NCT06098261View on ClinicalTrials.gov

Bioequivalence Study of Bilastine Tablets in Healthy Chinese Subjects

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 21, 2023

Primary Completion Date

December 3, 2023

Study Completion Date

September 27, 2024

Conditions
Healthy
Interventions
DRUG

Test (T) Bilastine

Specification: Bilastine 20mg. Produced and supplied by Shandong Hubble Kisen Biological Technology Co., Ltd.

DRUG

Reference (R) Bilastine

Specification: Bilastine 20mg. Produced by Menarini International Operations Luxembourg S.A.

All Listed Sponsors
lead

The Affiliated Hospital of Qingdao University

OTHER